Biology of Blood and Marrow Transplantation
Volume 13, Issue 1 , Pages 1-25 , January 2007

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myeloid Leukemia in Children: An Evidence-Based Review

  • Denise M. Oliansky

      Affiliations

    • Roswell Park Cancer Institute, Buffalo, New York
    • ,
  • J. Douglas Rizzo

      Affiliations

    • Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Peter D. Aplan

      Affiliations

    • NIH, NCI, CCR, Genetics Branch, Bethesda, Maryland
    • ,
  • Robert J. Arceci

      Affiliations

    • Kimmel Comprehensive Cancer Center, Baltimore, Maryland
    • ,
  • Louis Leone

      Affiliations

    • Children’s Oncology Group, Arcadia, California
    • ,
  • Yaddanapudi Ravindranath

      Affiliations

    • Childrens’s Hospital of Michigan and Wayne State University School of Medicine, Detroit, Michigan
    • ,
  • Jean E. Sanders

      Affiliations

    • Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington
    • ,
  • Franklin O. Smith III

      Affiliations

    • Cincinnati Children’s Hospital and Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio
    • ,
  • Fiona Wilmot

      Affiliations

    • Blue Shield of California, San Francisco, California
    • ,
  • Philip L. McCarthy Jr

      Affiliations

    • Roswell Park Cancer Institute, Buffalo, New York
    • ,
  • Theresa Hahn

      Affiliations

    • Roswell Park Cancer Institute, Buffalo, New York
    • Corresponding Author InformationCorrespondence and reprint requests: Theresa Hahn, PhD, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263.

Received 20 October 2006 ,Accepted 23 October 2006.

  • Image Result

    DFS from end of induction by diagnostic WBC count and matched family donor status for patients with AML in CR1. Reprinted with permission [11].

    DFS from end of induction by diagnostic WBC count and matched family donor status for patients with AML in CR1. Reprinted with permission [11].

  • Image Result

    EFS from the time of randomization or assignment to allo-BMT. Reprinted with permission [13].

    EFS from the time of randomization or assignment to allo-BMT. Reprinted with permission [13].

  • Image Result

    Estimated probability of 5-yr DFS in patients of AIEOP AML 87-92 studies by postremission treatment: allo-SCT, auto-SCT, or chemotherapy (CT). Slash indicates the patient without an event and with the

    Estimated probability of 5-yr DFS in patients of AIEOP AML 87-92 studies by postremission treatment: allo-SCT, auto-SCT, or chemotherapy (CT). Slash indicates the patient without an event and with the shortest follow-up. Reprinted with permission [16].

  • Image Result
    Probability of 7-yr DFS in NOPHO-AML93 according to postremission therapy in CR1. Reprinted with permission [21].

    Probability of 7-yr DFS in NOPHO-AML93 according to postremission therapy in CR1. Reprinted with permission [21].

 Major funding for this study was provided by the National Marrow Donor Program.

PII: S1083-8791(06)00734-8

doi: 10.1016/j.bbmt.2006.10.024

Biology of Blood and Marrow Transplantation
Volume 13, Issue 1 , Pages 1-25 , January 2007

Article Tools

* Image Usage & Resolution